Kairos Pharma, Ltd. filed a Form 8-K on November 5, 2026, disclosing that the company has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 (carotuximab).

Key Highlights

  • Award recognition: Kairos Pharma was named a winner of the 2026 Biotech Breakthrough Awards, according to the filing.
  • Category: The company received the award in the Cancer Immunology Solution of the Year category.
  • Drug involved: The recognition relates to work with ENV-105 (carotuximab).
  • Targeted conditions: ENV-105 is described in the filing as targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer.
  • Announcement date: The press release was issued on November 5, 2026, and is furnished as Exhibit 99.1.

Kairos Pharma's ENV-105 Recognized in 2026 Biotech Breakthrough Awards

According to the Form 8-K filed with the U.S. Securities and Exchange Commission, Kairos Pharma, Ltd. (NYSE American:KAPA) disclosed on November 5, 2026, that it had been named a winner of the 2026 Biotech Breakthrough Awards. The filing states the award falls in the category of "Cancer Immunology Solution of the Year," and is connected to the company's work with ENV-105, also known as carotuximab.

The filing indicates that ENV-105 is being developed to target cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. The disclosure was made under Item 8.01 (Other Events) of the Form 8-K. A press release dated November 5, 2026, was furnished as Exhibit 99.1 alongside the filing.

The filing notes that the information contained in the Current Report, including the furnished exhibit, "shall not be deemed 'filed' for any purpose of Section 18 of the Securities Exchange Act of 1934." The report was signed by John S. Yu, Chief Executive Officer of Kairos Pharma, Ltd. The company is incorporated in Delaware, is classified as an emerging growth company, and maintains its principal executive offices at 2355 Westwood Blvd, #139, Los Angeles, CA 90064.

What Was Disclosed

Kairos Pharma, Ltd. filed an 8-K on November 5, 2026, announcing it won the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year, related to ENV-105 (carotuximab) targeting drug resistance in metastatic prostate cancer and non-small cell lung cancer.